{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:16:31Z","timestamp":1784085391661,"version":"3.55.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Clenbuterol, a beta-agonist, has plausible mechanisms for treating amyotrophic lateral sclerosis (ALS). In this highly inclusive open-label trial (NCT04245709), we aimed to study the safety and efficacy of clenbuterol in patients with ALS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All participants received clenbuterol starting at 40 \u03bcg daily and increased to 80 \u03bcg twice daily. Outcomes included safety, tolerability, ALS Functional Rating Score (ALSFRS-R) progression, forced vital capacity (FVC) progression, and myometry. ALSFRS-R and FVC slopes measured during treatment were compared with slopes before treatment (calculated by assuming ALSFRS-R was 48 and FVC was 100% at ALS onset).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The 25 participants had a mean age of 59, mean disease duration of 43 months, ALSFRS-R score at enrollment 34, and FVC at enrollment 77%. Forty-eight percent were female, 68% were taking riluzole, and none were taking edaravone. Two participants experienced severe adverse events, neither related to the study. Twenty-four participants experienced adverse events, most commonly tremors\/jitters, cramps\/spasms, insomnia, and stiffness\/spasticity. Fourteen participants withdrew early from the trial, 13 due to adverse events. Patients who withdrew early were significantly older and more likely to be male. Per-protocol and intention-to-treat analyses showed meaningfully slower ALSFRS-R and FVC progression during treatment. Hand grip dynamometry and myometry changes were highly variable between participants; most declined slowly, but some showed improvements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Clenbuterol was safe but less tolerable at the doses we selected compared with an earlier Italian case series. Consistent with that series, our study suggested benefits on ALS progression. However, the latter result should be interpreted with caution as our study is limited by small sample size, large drop out, lack of randomization, and blinding and placebo controls. A larger, more traditional trial now seems warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000438","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:03:33Z","timestamp":1684854213000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis"],"prefix":"10.1097","volume":"24","author":[{"given":"Xiaoyan","family":"Li","sequence":"first","affiliation":[{"name":"Neurology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[{"name":"Pediatrics, Duke University, Durham, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Lutz","sequence":"additional","affiliation":[{"name":"Neurology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bedlack","sequence":"additional","affiliation":[{"name":"Neurology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2125.1981.tb01200.x","article-title":"Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo","volume":"12","author":"Whitsett","year":"1981","journal-title":"Br J Clin Pharmacol."},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000195203","article-title":"Study of the cardiovascular effects of clenbuterol in exercise-induced asthma","volume":"51","author":"Di Gioacchino","year":"1987","journal-title":"Respiration"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0020-7292(00)00254-X","article-title":"\u03b22-Adrenergic agonists and pelvic floor exercises for female stress incontinence","volume":"71","author":"Ishiko","year":"2000","journal-title":"Int J Gynecol Obstet."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/14660820600600558","article-title":"A pilot trial with clenbuterol in amyotrophic lateral sclerosis","volume":"7","author":"Soraru","year":"2006","journal-title":"Amyotroph Lateral Scler."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.archoralbio.2006.01.003","article-title":"The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat","volume":"51","author":"Matsumoto","year":"2006","journal-title":"Arch Oral Biol."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuropharm.2013.09.027","article-title":"Noradrenaline acting on astrocytic \u03b22-adrenoceptors induces neurite outgrowth in primary cortical neurons","volume":"77","author":"Day","year":"2014","journal-title":"Neuropharmacology"},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1073\/pnas.95.18.10920","article-title":"\u03b2-Adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT\/enhancer-binding protein \u03b4","volume":"95","author":"Colangelo","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.neulet.2005.12.007","article-title":"Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis","volume":"397","author":"Teng","year":"2006","journal-title":"Neurosci Lett."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in Pompe disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol Ther."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/21678421.2016.1249486","article-title":"Correlation between forced vital capacity and slow vital capacity for the assessment of respiratory involvement in amyotrophic lateral sclerosis: a prospective study","volume":"18","author":"Pinto","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2017.3339","article-title":"Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis","volume":"75","author":"Andrews","year":"2018","journal-title":"JAMA Neurol."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci."},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1212\/WNL.43.4.751","article-title":"The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials","volume":"43","author":"Pradas","year":"1993","journal-title":"Neurology"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/21678421.2016.1148169","article-title":"A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis","volume":"17","author":"Shefner","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.0000000000002941","article-title":"Quantitative strength testing in ALS clinical trials","volume":"87","author":"Shefner","year":"2016","journal-title":"Neurology"},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","article-title":"Progression in ALS is not linear but is curvilinear","volume":"257","author":"Gordon","year":"2010","journal-title":"J Neurol."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:02:57Z","timestamp":1746651777000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000438","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}